Company research
Eiger BioPharmaceuticals, Inc.
CIK 1305253Updated Nov 16, 2026
Securities
Historical securities (2)
EIGRQ · OTC · equity · closed Oct 1, 2024EIGRQ · OTC · equity · closed Oct 1, 2024Name history
Celladon Corp · through Mar 23, 2016
EIGRQ price & chart
Historical security
This listing closed Oct 1, 2024. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2023 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 38,826,000Source | 120,139,000Source | 126,402,000Source | 143,594,000Source |
| Property, Plant and Equipment, NetUSD | 627,000Source | 696,000Source | 613,000Source | 709,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 25,440,000Source | 25,798,000Source | 22,221,000Source | 28,864,000Source |
| Inventory, NetUSD | 1,556,000Source | 2,853,000Source | 2,612,000Source | — |
| Assets, CurrentUSD | 37,839,000Source | 117,535,000Source | 103,364,000Source | 137,806,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,161,000Source | 13,985,000Source | 9,361,000Source | 8,966,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 561,000Source | 653,000Source | 1,176,000Source |
| Other Assets, NoncurrentUSD | 360,000Source | 1,347,000Source | 4,510,000Source | 3,903,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 53,284,000Source | 64,829,000Source | 54,003,000Source | 48,559,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,000Source | 44,000Source | 35,000Source | 34,000Source |
| Retained Earnings (Accumulated Deficit)USD | -512,156,000Source | -437,193,000Source | -340,417,000Source | -306,500,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -169,000Source | -300,000Source | -149,000Source | -8,000Source |
| Stockholders' Equity Attributable to ParentUSD | -14,458,000Source | 55,310,000Source | 72,399,000Source | 95,035,000Source |
| Additional Paid in Capital, Common StockUSD | 497,866,000Source | 492,759,000Source | 412,930,000Source | 401,509,000Source |
| Liabilities and EquityUSD | 38,826,000Source | 120,139,000Source | 126,402,000Source | 143,594,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 53,284,000Source | 25,121,000Source | 29,901,000Source | 16,627,000Source |
| Operating Lease, Liability, CurrentUSD | 84,000Source | 491,000Source | 628,000Source | 582,000Source |
| Accounts Payable, CurrentUSD | 2,115,000Source | 8,975,000Source | 7,765,000Source | 4,640,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 83,000Source | 116,000Source | 738,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,966,000Source | 15,655,000Source | 13,699,000Source | 11,405,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 98,900,000Source | 88,800,000Source | 128,900,000Source |
| Deferred Tax Liabilities, NetUSD | 21,000Source | 128,000Source | 137,000Source | 247,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 39,625,000Source | — | 31,194,000Source |
| Long-term Debt, Current MaturitiesUSD | 41,119,000Source | 0Source | 7,809,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 39,625,000Source | 23,986,000Source | 31,194,000Source |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -33,917,000Source | -65,051,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 275,000Source | 292,000Source | 276,000Source | 167,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,008,000Source | 8,317,000Source | 7,901,000Source | 5,973,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -84,000Source | -828,000Source | 2,576,000Source | — |
| Increase (Decrease) in InventoriesUSD | -1,626,000Source | 1,367,000Source | 2,424,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -6,835,000Source | 1,152,000Source | 3,234,000Source | -1,899,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -74,548,000Source | -83,010,000Source | -71,342,000Source | -63,185,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 74,228,000Source | 9,632,000Source | 61,532,000Source | -44,787,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 234,000Source | 340,000Source | 225,000Source | 258,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 41,000Source | 76,955,000Source | 3,167,000Source | 97,463,000Source |
| Repayments of Long-term DebtUSD | 0Source | 33,277,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -358,000Source | 3,577,000Source | -6,643,000Source | -10,509,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 25,440,000Source | 25,798,000Source | 22,221,000Source | 28,864,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,972,000Source | 2,885,000Source | 2,783,000Source | 2,791,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -79,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 5,008,000Source | 8,317,000Source | 7,901,000Source | 5,973,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,494,000Source | 1,238,000Source | 776,000Source | 804,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 98,900,000Source | 88,800,000Source | 128,900,000Source |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | 0Source | — | — | — |
| DepreciationUSD | 300,000Source | 300,000Source | 300,000Source | 167,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 100,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -1,144,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | — | 20,559,000Source |
| Income Tax Expense (Benefit)USD | 6,000Source | 23,000Source | 64,000Source | 0Source |
| Inventory Write-downUSD | 8,000Source | 1,043,000Source | 0Source | — |
| Investment Income, InterestUSD | 2,208,000Source | 1,082,000Source | 158,000Source | 704,000Source |
| Net Income (Loss) Attributable to ParentUSD | -74,963,000Source | -96,776,000Source | -33,917,000Source | -65,051,000Source |
| Operating ExpensesUSD | — | — | — | 62,149,000Source |
| Operating Lease, ExpenseUSD | — | 600,000Source | 600,000Source | 600,000Source |
| Other Nonoperating Income (Expense)USD | 87,000Source | -963,000Source | 46,487,000Source | -12,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 66,402,000Source | 3,040,000Source | 96,779,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 39,841,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 0Source | 234,000Source | 361,000Source | 520,000Source |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Total RevenueUSD | 15,773,000Source | 13,484,000Source | 12,142,000Source | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 25,204,000Source | 29,105,000Source | 23,900,000Source | — |
| Operating Income (Loss)USD | -71,786,000Source | -92,740,000Source | -76,939,000Source | -62,149,000Source |
| Other Nonoperating Income (Expense)USD | 87,000Source | -963,000Source | 46,487,000Source | -12,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -74,957,000Source | -96,753,000Source | -33,853,000Source | — |
| Income Tax Expense (Benefit)USD | 6,000Source | 23,000Source | 64,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -74,963,000Source | -96,776,000Source | -33,917,000Source | -65,051,000Source |
| Earnings Per Share, BasicUSD per share | -50.78Source | -2.32Source | — | — |
| Earnings Per Share, DilutedUSD per share | -50.78Source | -2.32Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,476,247Source | 41,628,207Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,476,247Source | 41,628,207Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 87,559,000Source | 106,224,000Source | 89,081,000Source | — |
| Current Income Tax Expense (Benefit)USD | 6,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 100,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | 20,559,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -75,002,000Source | — | — | — |
| Interest ExpenseUSD | 5,466,000Source | 4,132,000Source | 3,559,000Source | 3,594,000Source |
| Investment Income, InterestUSD | 2,208,000Source | 1,082,000Source | 158,000Source | 704,000Source |
| Operating ExpensesUSD | — | — | — | 62,149,000Source |
| Operating Lease, ExpenseUSD | — | 600,000Source | 600,000Source | 600,000Source |
| Research and Development ExpenseUSD | 62,331,000Source | 75,282,000Source | 64,436,000Source | 41,590,000Source |